Owl Creek Wealth Partners’s Vaxcyte PCVX Stock Holding History

Owl Creek Wealth Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16K	Hold	275	–	–	﹤0.01%	697
2026 Q1	$16K	Buy	+275	New	+$14.9K	0.01%	639

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Owl Creek Wealth Partners's PCVX Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Vaxcyte (PCVX) position steady in Q2 2026 at 275 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #697.

Owl Creek Wealth Partners first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Owl Creek Wealth Partners held 275 shares of Vaxcyte worth $16K as of Q2 2026.
Owl Creek Wealth Partners left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #697 holding.
Owl Creek Wealth Partners first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.